TR200400941T4 - Lipid kinazların modülatörlerinin taranması için yöntemler ve bileşimler - Google Patents

Lipid kinazların modülatörlerinin taranması için yöntemler ve bileşimler

Info

Publication number
TR200400941T4
TR200400941T4 TR2004/00941T TR200400941T TR200400941T4 TR 200400941 T4 TR200400941 T4 TR 200400941T4 TR 2004/00941 T TR2004/00941 T TR 2004/00941T TR 200400941 T TR200400941 T TR 200400941T TR 200400941 T4 TR200400941 T4 TR 200400941T4
Authority
TR
Turkey
Prior art keywords
methods
lipid kinases
compositions
kinases
screening modulators
Prior art date
Application number
TR2004/00941T
Other languages
Unknown language ( )
English (en)
Inventor
Normant Emmanuel
Melendez Alirio
Casamitjana Olivier
Moreau Fran�Ois
Original Assignee
Warner-Lambert Company Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc. filed Critical Warner-Lambert Company Llc.
Publication of TR200400941T4 publication Critical patent/TR200400941T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Mevcut bulus, lipid kinazlarin aktivitesini modüle eden bilesiklerin tarama yöntemleri ile ilgilidir. Bu daha fazla tercih edildigi üzere, lipid kinazlarin, daha spesifik olarak sfingosin kinazlarin aktivitesini modüle eden bilesikleri taramak için SPA teknolojisine dayanir. Bulus ayni zamanda sözü edilen yöntemler ile teshis edilen bilesiklerin yani sira, yukaridaki yöntemlerin gerçeklestirilmesinde bilesimleri, ürünleri, kitleri v.b. ve bunlarin kullanimlarini da içine alir.
TR2004/00941T 2000-09-29 2001-09-28 Lipid kinazların modülatörlerinin taranması için yöntemler ve bileşimler TR200400941T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402684A EP1195604A1 (en) 2000-09-29 2000-09-29 Methods and compositions for screening modulators of lipid kinases

Publications (1)

Publication Number Publication Date
TR200400941T4 true TR200400941T4 (tr) 2004-06-21

Family

ID=8173885

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/00941T TR200400941T4 (tr) 2000-09-29 2001-09-28 Lipid kinazların modülatörlerinin taranması için yöntemler ve bileşimler

Country Status (12)

Country Link
US (1) US6723525B2 (tr)
EP (2) EP1195604A1 (tr)
JP (1) JP2004509638A (tr)
AT (1) ATE263373T1 (tr)
AU (1) AU2001289939A1 (tr)
CA (1) CA2423889A1 (tr)
DE (1) DE60102539T2 (tr)
DK (1) DK1195605T3 (tr)
ES (1) ES2218351T3 (tr)
PT (1) PT1195605E (tr)
TR (1) TR200400941T4 (tr)
WO (1) WO2002027318A1 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US8945932B2 (en) 2004-07-06 2015-02-03 Perkinelmer Health Sciences, Inc. Methods and compositions for detecting and isolating phosphorylated molecules using hydrated metal oxides
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
EP1913390B1 (en) * 2005-08-11 2012-05-30 PerkinElmer LAS, Inc. Assay methods using hollow particles and kits containing them
DE602006012072D1 (de) * 2005-10-12 2010-03-18 Allergan Inc Tests der molekularen oder subzellulären interaktivität unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
US9200309B2 (en) * 2010-06-28 2015-12-01 Daiichi Sankyo Company, Limited Method for screening for S1P lyase inhibitors using cultured cells
EP2727926A4 (en) 2011-06-28 2015-03-04 Daiichi Sankyo Co Ltd ESTER DERIVATIVE OF PHOSPHORIC ACID

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
DE3483099D1 (de) 1984-03-15 1990-10-04 Immunex Corp Test zur sofortigen feststellung von liganden, testsatz und seine herstellung.
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
EP0502123A4 (en) * 1989-12-01 1992-11-04 Packard Instrument Company, Inc. Scintillation proximity radioimmunoassay using solid scintillator support body
US5677189A (en) * 1995-06-29 1997-10-14 Oncomembrane, Inc. Method for quantifying sphingosine and for diagnosing platelet activation
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
WO1999061581A2 (en) * 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
CA2335941C (en) * 1998-06-29 2011-03-22 Barry James Maurer Treatment of hyperproliferative disorders
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3

Also Published As

Publication number Publication date
US6723525B2 (en) 2004-04-20
DE60102539D1 (de) 2004-05-06
EP1195605A1 (en) 2002-04-10
DK1195605T3 (da) 2004-08-02
ES2218351T3 (es) 2004-11-16
EP1195605B1 (en) 2004-03-31
PT1195605E (pt) 2004-08-31
DE60102539T2 (de) 2005-04-07
WO2002027318A1 (en) 2002-04-04
AU2001289939A1 (en) 2002-04-08
CA2423889A1 (en) 2002-04-04
JP2004509638A (ja) 2004-04-02
EP1195604A1 (en) 2002-04-10
US20020042091A1 (en) 2002-04-11
ATE263373T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
MA28985B1 (fr) Analogues de loxapine et methodes d'utilisation
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
DK1311482T3 (da) Ikke-imidazolaryloxypiperidiner som H3-receptorligander
ATE246938T1 (de) Anwendung der mesenchymalen stammzellen als immunsuppressiva
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
BRPI0503397A (pt) composição de coloração, processo de coloração e uso de uma composição
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
DE60321333D1 (de) Tetrahydropyranyl-cyclopentyl-tetrahydropyridopyridin-modulatoren der chemokin-rezeptor-aktivität
ECSP034874A (es) Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
ATE521397T1 (de) Attraktionssystem und verfahren zur bereitstellung einer attraktion
BR9509665A (pt) Composto composições e métodos
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
CR7807A (es) Piperacinil y diacepanil benzamidas y benztioamidas
TR199900856T2 (tr) Bronsla ilgili terapi maddeleri olarak benzonaftiridinler
WO2005123043A3 (en) Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
FR2862223B1 (fr) Emulsion renfermant des portions de spheres creuses organosiliconees.
TR200400941T4 (tr) Lipid kinazların modülatörlerinin taranması için yöntemler ve bileşimler
DE69832797D1 (de) Neurturin-rezeptor